--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-234487" form_type: "8-K" ticker: "OKUR" cik: "0001637715" company_name: "OnKure Therapeutics, Inc." filed_at: "2024-10-08T23:59:59+00:00" generated_at: "2026-05-30T18:03:09.324494+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE ## Summary - Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares. - PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M. - Reverse stock split 1:10, name change to OnKure Therapeutics, ticker changes from RPHM to OKUR. - Lead candidate OKI-219 (PI3Kα H1047R inhibitor) in Phase 1; early data expected Q4 2024. - New board and management: Nicholas Saccomano CEO, Samuel Agresta CMO, Jason Leverone CFO. ## SEC filing metadata - accession: 0001193125-24-234487 - form_type: 8-K - ticker: OKUR - cik: 0001637715 - company_name: OnKure Therapeutics, Inc. - filed_at: 2024-10-08T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.01, 3.02, 9.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-234487 - JSON: https://secwatch.observer/filing/0001193125-24-234487.json - Plain text: https://secwatch.observer/filing/0001193125-24-234487.txt ## Key facts - Executive change Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class I Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc.. - Action: appointed - Role: Chair of the Board source text: Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class II Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class I Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class III Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class II Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class II Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm - Executive change Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc.. - Action: appointed - Role: Class III Director source text: Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors. evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.